Rhopressa Solution/ Drops
Product Images NDC 70727-497

15 FDA label images from Alcon Laboratories, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Rhopressa (NDC 70727-497). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alcon Laboratories, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label (Bottlelabel)

Bottle Label (Bottlelabel)
The image shows a pharmaceutical label for Rhopressa (netarsudil ophthalmic solution) 0.02%, an ophthalmic topical solution in a 2.5 mL package. The label includes instructions for topical eye application and notes the product is sterile and Rx only. The labeler is Alcon Laboratories, Inc., Fort Worth, TX.*
FDA Label Image

Sample Bottle Label (Samplebottlelabel)

Sample Bottle Label (Samplebottlelabel)
The image shows a carton label for Rhopressa 0.02% (netarsudil ophthalmic solution) 2.5 mL, an ophthalmic topical solution by Alcon Laboratories, Inc. It includes the NDC 70727-497-99 and indicates the product is a sterile Rx-only sample not for resale. The label also advises to see the carton for storage conditions and features space for lot number and expiration date.*
FDA Label Image

Carton Label (Carton 25)

Carton Label (Carton 25)
Rhopressa 0.02% (netarsudil ophthalmic solution) sterile eye drops in a 2.5 mL topical ophthalmic solution. The packaging label shows the brand name Rhopressa with strength 0.02%, for topical application in the eye, Rx only. Labeler is Alcon Laboratories, Inc. Storage instructions note keeping the product between 2°C and 8°C before opening, with specific handling after opening.*
FDA Label Image

Bottle Label (Label 25)

Bottle Label (Label 25)
Rhopressa 0.02% (netarsudil ophthalmic solution) 2.5 mL topical ophthalmic solution vial label. The label includes text indicating Rx only, sterile, manufacturer Alcon Laboratories, Inc. Fort Worth, TX, and storage directions. The label shows the NDC 70727-497-25 and lot and expiration date fields.*
FDA Label Image

Sample Carton Label (Carton 99)

Sample Carton Label (Carton 99)
Packaging label for Rhopressa (netarsudil ophthalmic solution) 0.02%, a 2.5 mL topical ophthalmic solution by Alcon Laboratories. The label indicates prescription use only, sterile solution, and includes dosage, storage instructions, and manufacturing details. The label features the product name, active ingredient concentration, and clear usage directions for eye application.*
FDA Label Image

Sample Bottle Label (Label 99)

Sample Bottle Label (Label 99)
Label for Rhopressa (netarsudil ophthalmic solution) 0.02%, a 2.5 mL sterile ophthalmic solution by Alcon Laboratories, Inc. The label indicates it is for topical application in the eye, prescription only, and includes lot and expiration details with a QR code.*
FDA Label Image

Netarsudil Structural Formula (Molecule)

Netarsudil Structural Formula (Molecule)
Chemical structure diagram of netarsudil, the active ingredient in Rhopressa ophthalmic solution. The structure includes the netarsudil molecule with surrounding molecular groups depicted.*
FDA Label Image

Study 301: Subjects With Baseline Iop < 25 Mmhg (Image 01)

Study 301:  Subjects With Baseline Iop < 25 Mmhg (Image 01)
A table and accompanying forest plot from Study 301 showing mean intraocular pressure (IOP) values and changes from baseline at various time points (8am, 10am, 4pm) for subjects with baseline IOP less than 25 mmHg. The data compares Rhopressa (netarsudil ophthalmic solution 0.2 mg/mL) versus Timolol, with mean IOP and change from baseline presented for Day 15, Day 43, and Day 90 visits, along with the difference between Rhopressa and Timolol including 95% confidence intervals.*
FDA Label Image

Study 301: Subjects With Baseline Iop >= 25 And < 27 Mmhg (Image 02)

Study 301:  Subjects With Baseline Iop >= 25 And < 27 Mmhg (Image 02)
A horizontal dot plot chart comparing intraocular pressure (IOP) changes from baseline at different times (8am, 10am, 4pm) across Days 15, 43, and 90 in a study of subjects with baseline IOP between 25 and 27 mmHg. It compares Rhopressa (netarsudil) versus Timolol, showing mean differences and 95% confidence intervals at each time point. The data is tabulated alongside the graph, detailing IOP measurements for each treatment group and visit time.*
FDA Label Image

Study 302: Subjects With Baseline Iop < 25 Mmhg (Image 03)

Study 302: Subjects With Baseline Iop < 25 Mmhg (Image 03)
A data table and forest plot from a clinical study comparing intraocular pressure (IOP) changes over time at 8am, 10am, and 4pm visits for Rhopressa (netarsudil) and Timolol in subjects with baseline IOP less than 25 mmHg. The table shows mean IOP values at baseline and changes from baseline on Days 15, 43, and 90, alongside the difference (with 95% confidence intervals) between Rhopressa and Timolol at each time point. The plot visually represents these differences with markers and confidence intervals around zero.*
FDA Label Image

Study 302: Subjects With Baseline Iop >= 25 And < 27 Mmhg (Image 04)

Study 302: Subjects With Baseline Iop >= 25 And < 27 Mmhg (Image 04)
A forest plot chart comparing intraocular pressure (IOP) changes from baseline between Rhopressa (netarsudil) and Timolol at different visits and times of day (8am, 10am, 4pm). The chart includes mean differences with 95% confidence intervals, showing study data over baseline, Day 15, Day 43, and Day 90 for subjects with baseline IOP between 25 and 27 mmHg.*
FDA Label Image

Study 304: Subjects With Baseline Iop < 25 Mmhg (Image 05)

Study 304: Subjects With Baseline Iop < 25 Mmhg (Image 05)
A clinical study results chart comparing the effects of Rhopressa (netarsudil ophthalmic solution 0.2 mg/mL) and Timolol on intraocular pressure (IOP) in subjects with baseline IOP less than 25 mmHg. The chart presents mean IOP values at various times (8am, 10am, 4pm) across baseline, day 15, day 43, and day 90 visits, along with differences between treatments and 95% confidence intervals shown as horizontal error bars.*
FDA Label Image

Study 304: Subjects With Baseline Iop >= 25 And < 30 Mmhg (Image 06)

Study 304: Subjects With Baseline Iop >= 25 And < 30 Mmhg (Image 06)
A data table with a corresponding forest plot showing intraocular pressure (IOP) measurements and changes from baseline for subjects treated with Rhopressa (netarsudil ophthalmic solution) versus Timolol. The table lists baseline IOP values at 8am, 10am, and 4pm, and changes from baseline at Days 15, 43, and 90. The forest plot visualizes the difference in IOP change between Rhopressa and Timolol with 95% confidence intervals at various time points.*
FDA Label Image

Carton Label (Cartonlabel)

Carton Label (Cartonlabel)
Rhopressa 0.02% (netarsudil ophthalmic solution) 2.5 mL carton label for topical ophthalmic use, containing prescription eye drops. Label features dosage information, manufacturer Alcon Laboratories, Inc., storage instructions, and barcodes. The solution contains active netarsudil mesylate 0.285 mg per mL and uses benzalkonium chloride as preservative.*
FDA Label Image

Sample Carton Label (Samplecartonlabel)

Sample Carton Label (Samplecartonlabel)
Carton label for Rhopressa (netarsudil ophthalmic solution) 0.02%, a 2.5 mL sterile topical ophthalmic solution by Alcon Laboratories, Inc. The label includes dosage instructions, storage conditions, preservative and inactive ingredients, and regulatory details, along with a red banner indicating 'SAMPLE - Not for Resale.'*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.